The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

For patients with nonvalvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use ...

SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

For patients with atrial fibrillation, the use of oral anticoagulant therapy to prevent stroke is limited by the risk of bleeding. Left atrial appendage closure is considered for patients who are ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

A new Watchman device at McLaren Port Huron offers eligible AFib patients an alternative to long‑term blood thinners to help ...

Boston Scientific stock tumbled Monday on mixed test results for its Watchman device in patients at risk of having a stroke.

Midland Memorial Health is now offering a new procedure called Left Atrial Appendage Occlusion. Doctor Sulay Patel will be ...

MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration approval for the latest-generation ...